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Abstract 
 
Background: Prognostic models for patients with chronic heart failure are generally based 
on a single assessment but treatment is often given with the intention of changing risk; re- 
evaluation of risk is an important aspect of care. The prognostic value of serial measurements 
of natriuretic peptides for the assessment of changes in risk is uncertain. 
Aims: To evaluate the prognostic value of serial measurements of plasma amino-terminal 
pro-brain natriuretic peptide (NT-proBNP) during follow-up of out-patients with chronic 
heart failure (CHF). 
Methods: Patients diagnosed with CHF between 2001 and 2014 at a single out-patient clinic 
serving a local community were included in this analysis. NT-proBNP was measured at the 
initial visit and serially during follow-up. Only patients who had one or more measurements of 
NT-proBNP after baseline, at 4, 12 and/or 24 months were included. 
Results: At baseline, amongst 1,998 patients enrolled, the median age was 73 (IQR: 64-79) 
years, 70% were men, 31% were in NYHA class III/IV, 58% had a reduced ejection fraction 
and 77% had NT-proBNP >400 pg/ml. Median follow-up was 4.8 (IQR 2.5-8.6) years. Serial 
measurements of NT-proBNP improved prediction of all-cause mortality at 3 years (c- 
statistic=0.71) compared with using baseline data only (c-statistic=0.67; p<0.001) but a 
model using only the most recent NT-proBNP had an even higher c-statistic (0.72; p<0.001). 
Similar results were obtained based on long-term prediction of mortality using all available 
follow-up data. 
Conclusions: Serial measurement of NT-proBNP in patients with CHF improves prediction of 
all-cause mortality. However, using the most recent value of NT-proBNP has similar 
predictive power as using serial measurements. 
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Introduction 
 
Plasma concentrations of N-terminal pro B-type natriuretic peptide (NT-proBNP) are 
strongly associated with prognosis in patients with chronic heart failure (CHF). 1-5 
Prognostic models of CHF are generally based on a single assessment but in clinical practice 
risk varies over time as disease progresses, complications and co-morbidities develop and 
treatment that is intended to reduce risk is implemented. In clinical practice, health 
professionals evaluate risk serially. In clinical trials, the effect of treatment on NT-proBNP 
has often predicted outcome, 6 although this may not be true for some interventions such as 
beta-blockers. Recently the use of repeated measurements of NT-proBNP for predicting outcome 
have been studied for some chronic and acute setting (Supplementary Table S1). However, the 
prognostic value of serial measurements of natriuretic peptides for the assessment of changes in 
long-term risk in clinical practice has rarely been investigated and the value of doing so is 
uncertain. Some risk markers will be relatively fixed (eg:- age, sex and aetiology of disease) 
but other will be dynamic and fluctuate (for example, renal function). If serial measurements 
of NT-proBNP are more strongly related to prognosis than a single baseline value, it may be 
a dynamic marker that can be used to track risk. 
The purpose of the present study was to investigate the relationship between all-cause 
mortality and repeated measurements of NT-proBNP compared with a single baseline or most 
recent value of NT-proBNP. 
 
 
 
Methods 
 
Study Population 
 
Patients referred to a community heart failure clinic (Kingston-upon-Hull, UK) for the 
assessment of heart failure symptoms were invited to participate. A history and examination 
were performed, and patients underwent electrocardiography, echocardiography and had 
routine haematology and biochemical investigations. If heart failure was confirmed, patients 
were offered serial follow-up in the heart failure clinic. NT-proBNP was measured at baseline, 
and then at approximately 4 months, 12 months and yearly thereafter. Only patients who had one 
or more follow-up measurements of NT-proBNP were included in this analysis. 
 
Samples for the measurement of NT-proBNP were collected in ethylene-diamine-tetra-acetic 
tubes, spun at 3000 r.p.m for 15 minutes in a cooled (4°C) centrifuge and the plasma was 
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stored at -80°C until batch analysed using the Elecsys proBNP assay (Roche Diagnostics, Basel, 
Switzerland). 
Prospectively collected clinical data and blood samples from a single heart failure clinic 
were used in this study. The primary outcome of interest was all-cause mortality. Data for 
deaths were collected from the hospital’s electronic systems, supplemented by information 
from patients, discharge letters and their family doctors. 
Prior to inclusion, all patients provided written informed consent for their data to be used and 
the study was carried out in accordance with the Helsinki Declaration II and the European 
Standards for Good Clinical Practice. Ethical approval was granted by the Hull and East 
Yorkshire Local Research Ethics Committee. 
 
 
 
Statistical methods 
 
Continuous variables are presented as medians and the inter-quartile ranges and categorical 
variables are expressed as percentages. Correlations between the repeated NT-proBNP 
measurements were assessed with scatter plots and Pearson’s correlation coefficients. The 
assumptions of Cox regression model, such as the proportional hazards and linearity were 
assessed. 
Two main analyses were conducted. Firstly, the association between NT-proBNP 
measurements and survival at three years was studied and the predictive value of NT-proBNP 
was assessed. The strategy included analysis of the relation between outcome and: (a) 
baseline NT-proBNP; (b) repeated NT-proBNP measurements as a time-dependent covariate 
using an extended Cox regression model 7allowing for different patients having different 
numbers of NT-proBNP measurements at varying time-points and (c) only the most recent 
NT-proBNP. 
 
Secondly, a robust joint modelling of longitudinal and survival data 8 was used to evaluate the 
association between all repeated NT-proBNPs and time to all-cause mortality. The aim was to 
assess whether there was any association between the repeated of plasma NT-proBNP and 
outcome. The patients who had at least two measures of NT-proBNP used in the first analysis 
plus further available NT-proBNP measurements were included in this analysis. The joint model 
is effectively a two-stage process. First, an analysis of the longitudinal data for NT-proBNP 
over time is performed using a linear mixed effects model. In the second stage, a Cox 
Page 5 of 13  
proportional hazard model is used for survival data.  These two stages are linked through shared 
random effects to evaluate the association between the values of NT-proBNP and time to all-
cause mortality. 
For the longitudinal sub-model the random effects of both intercept and slope were included to 
allow variations in each individually. Baseline age, sex, estimated glomerular filtration rate (eGRF) 
were used as the fixed effects, and an interaction between time and heart rhythm was included. For 
the Cox-regression sub-model, pre-specified baseline variables included age, sex, and eGFR were 
used. Individual patient prediction was conducted according to the trajectory of NT-proBNP. 
Statistical analysis was carried out using R version 3.0.1 and Stata software package. The two-
tailed level of statistical significance was set at p<0.05. 
 
 
Results 
Of 1,998 patients with at least two measurements of NT-proBNP, 70% were men. At baseline, 
their median age was 73 (IQR: 64-79) years, 31% were in NYHA class III/IV and 77% had 
NT-proBNP >400 ng.L
-1
. Overall three-year mortality for patients with at least two 
measurements was 12.7%. 
Patients who died at 3 years were older and more likely to be men, have ischaemic heart 
disease (IHD) and more severe symptoms, more likely to have atrial fibrillation, COPD and 
had a lower eGFR, systolic BP and haemoglobin, and higher heart rate and NT-proBNP than 
those who survived. Patients who survived were more likely to be prescribed beta-blockers 
and ACEi/ARBs (Table 1). 
There were strong positive linear correlations between baseline log(NT-proBNP) and each of 
repeated measurements of log(NT-proBNP) at 4 months, 12 months and 24 months 
regardless of heart rhythm (supplementary Table S2). Patients in atrial fibrillation had a 
consistently higher and patients in sinus rhythm consistently had lower median plasma NT-
proBNP at all time-points. Correlations were stronger for closer time-points (Figure 1, 
supplementary Table S2). 
Baseline NT-proBNP, time-dependent covariate NT-proBNP and most recent NT-proBNP 
were all significant predictors of all-cause mortality at 3 years (Table 2) (p<0.0001 for all). 
Serial measurements and the most recent NT-proBNP were better predictors of prognosis 
than were baseline values. Similar results were obtained when the models were adjusted for 
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age and sex. 
1,998 patients with baseline and follow-up values for NT-proBNP (N=10,362) were included 
in the joint-modelling analysis, of whom 770 (39%) died. The median (IQR) follow-up time 
was 4.8 (2.5-8.6) years. The minimum follow-up time was 0.3 years and the maximum was 
13.7 years. 
There was a strong association between serial NT-proBNP values as a time-dependent 
covariate and all-cause mortality (Supplementary Table S3). A unit increase in log(NT-
proBNP) corresponded to a 3.76 - fold increase in the risk for death (95%CI: 3.15-4.56, 
P<0.0001). The hazard ratios (HR) decreased when the most recent measurement of NT-
proBNP was excluded (HR: 3.01 (2.20-3.21)). The HR of log(NT-proBNP) in the joint model 
was approximately twice as high as the model including only the baseline data. However, the 
Cox regression using only the most recent measurement of NT-proBNP gave a HR very 
similar to that in the joint model (HR: 3.73 (3.20-4.34)), with a higher z value of 16.89 
(p<0.0001). A significant interaction between the time and baseline SR (p=0.01) was observed. 
Figure 2 shows an example of the dynamic change in predicted risk based on an increasing 
number of NT-proBNP measurements. At baseline, the patient’s NT-proBNP was high, 
decreasing quickly and becoming stable from 2 years onward. The graphs show that the 
probabilities for survival gradually improved as NT-proBNP decreased. Supplementary 
Figures S1 and S2 show a patient who died and another who had a plasma NT-proBNP 
persistently <500ng/L. 
 
 
 
Discussion 
To the best of our knowledge, this is the first paper to apply joint-modelling to study the 
dynamic association between serial measurements of NT- proBNP and survival. It suggests 
that NT-proBNP is a useful measurement for monitoring changes in prognosis, and 
presumably reflects the combined effects of disease progression, response to therapy and, for 
some, recovery of cardiac function. 9 Clearly, there must be a relationship between changes 
in and values of NT-proBNP but the most recent value of NT-proBNP conveys the most 
important prognostic information.10 Our results cannot be taken as evidence that pursuing a 
particular target for NT-proBNP is the correct approach, as confirmed by the recent GUIDE-
IT trial.11Basing clinical decisions on a single measurement is simple and has several other 
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advantages. Previous measurements may not be available. Measuring change is also complex. 
It is not clear whether absolute or relative change is more important or the rate of change, and 
therefore the timing of samples, or what value should be used as the reference point from 
which change is measured; values may go up as well as down and the change between the 
first and most recent test may be very different from the change between the two most recent 
ones. 
Hopefully, one day, the aim will be to return values of NT-proBNP observed in patients with 
heart failure back into the normal range for the healthy population, although, despite 
implementation of guideline-recommended therapies, this rarely occurred in this cohort of 
patients. Further advances in the treatment of heart failure may increase the proportion of 
patients that achieve a normal value for NT-proBNP and if associated with control of 
symptoms and a good prognosis, this might be termed ‘remission’ of heart failure. 12 
Numerous studies have shown the prognostic value of natriuretic peptides for patients with 
chronic heart failure and various other medical conditions. 12, 10, 13-20 However, they have not 
proved consistently valuable for assessing prognosis in acute heart failure (Supplementary 
Table S1_A). 21-25, 26-27 Curiously, this may reflect their ability to track changing prognostic 
risk rather than their failure. A patient with decompensated heart failure, left untreated, is 
near to death. Treatment will usually reduce NT-proBNP and improve prognosis. If 
natriuretic peptides were good prognostic markers in the acute setting, this would imply that 
they did not track with changing prognosis. In this setting, changes in natriuretic peptides 
might possibly provide additional information to achieved values, 24, 28 but when patients 
enter a more stable chronic phase of their illness our results are likely to apply. 
Few studies 10, 14, 17 have examined the relationship of changes in natriuretic peptides and 
outcome in out-patients with chronic heart failure [Supplementary Table S1_B]. In a small 
sample of patients with much fewer measurements of NT-proBNP and over a much shorter 
time-frame, we found similar results.16 In a study of 2975 elderly adults without heart failure 
in whom NT-proBNP had been measured twice, 2-3 years apart, the second measurement 
further improved prediction of incident heart failure and cardiovascular death. 29 However, 
the possibility that baseline values added nothing to the follow-up value was not explored. 
The prognostic value of natriuretic peptides appears similar for most if not all phenotypes of 
chronic heart failure. 13, 14, 16 However, for each of these phenotypes, plasma concentrations of 
NT-proBNP were relatively stable for most patients despite attempts to control symptoms and 
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deliver guideline-recommended therapy. 
Previous analyses have often failed to take into account the possibility that serial 
measurements of NT-proBNP are highly correlated. 13-15 Joint modelling of longitudinal and 
survival data is useful since it reduces the bias in estimating the association between 
repeated measurements and time to event 8and provides an updated individual survival 
probability when a new measurement of NT-proBNP becomes available.  
 
Limitations: An important limitation is that joint modelling, currently, allows only one 
variable (NT-proBNP in this case) to be used serially in the model. In addition, we have not 
reported rates of ICD/CRT implantation at baseline, partly because implant rates were low, and 
partly because many patients had a device implanted during follow up. Furthermore, the 
c-statistics we report are invariably much less than 1 reflects the impact of other 
variables, such as renal function and co-morbidities, on outcome. However, the aim of 
the study was to explore whether the history of how the NT-proBNP reached its present 
value matters. We have therefore not used further complex modelling to include all 
possible variables in all possible models to maximise the value for c-statistics. 
Supplementary table S2 shows how we did not have data at every time point in each 
subject. However, one of the advantages of using joint modelling is that it can cope with 
missing values and does not require equal time intervals of longitudinal data. Further 
studies are needed to validate the findings. 
 
 
 
Conclusions 
In conclusion, serial measurement of NT-proBNP may be useful to monitor changes in 
prognostic risk but it is the last measured value that carries the most information. Reductions in 
NT-proBNP may indicate improving prognosis but it is the value achieved that indicates what 
the prognosis has improved to; in other words, what the prognosis actually is! 
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Figure legend 
 
Figures 1: Relationship (showing lines of identity) between baseline log(NT-proBNP) and 
other measurements of log(NT-proBNP) at 4 months, 12 months and 24 months for patients 
who had SR (the top row), and not SR (the bottom row). 
Figure 2: Dynamic survival probabilities with 95% CI based on various measurements of 
NT-proBNP for a patient whose values fell. The vertical dotted lines show the time point of 
the last log(NT-proBNP) measurement; prior values are shown to the left of the vertical 
line. The curves to the right are the survival probabilities incorporating all the NT-proBNP 
data to that point (x-axis: Time (years), y-axis: Longitudinal Outcome shows the observed 
values of log10(NT-proBNP) at each follow-up time point. 
Supplementary Figure S1-S2: Dynamic survival probabilities with 95% CI based on various 
measurements of NT-proBNP for a patient (Figure S1 shows the patient who died and 
Figure S2 shows the patient who survived). The vertical dotted lines show the time point of 
the last log(NT-proBNP) measurement; prior values are shown to the left of the vertical line. 
The curves to the right are the survival probabilities incorporating all the NT-proBNP data to 
that point (x-axis: Time (years), y-axis: Longitudinal Outcome shows the observed values of 
log10(NT-proBNP) at each follow-up time point. 
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Figure 1: Relationship (showing lines of identity) between baseline log(NT-proBNP) and 
other measurements of log(NT-proBNP) at 4 months, 12 months and 24 months for patients 
who had SR (the top row), and not SR (the bottom row). 
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 Figure 2: Dynamic survival probabilities with 95% CI based on various measurements of 
NT-proBNP for a patient whose values fell. The vertical dotted lines show the time point of 
the last log(NT-proBNP) measurement; prior values are shown to the left of the vertical line. 
The curves to the right are the survival probabilities incorporating all the NT-proBNP data to 
that point (x-axis: Time (years), y-axis: Longitudinal Outcome shows the observed values of 
log10(NT-proBNP) at each follow-up time point. 
 
Table1: Baseline patient characteristics 
 Missing All patients 
(n=1,998) 
Survived at 3 years Died at 3 years 
Total 
(n = 1,744) 
Not SR 
 (n=527) 
SR  
(n=1,217) 
p-value* Total  
(n = 254) 
Not SR  
(n=87) 
SR 
 (n=167) 
p-value*  
 
Age (yrs) 1 73 (64-79) 72 (66-78) 74 (67-81) 70 (63-77) <0.001 76 (70-82) 78 (72-83) 76 (69-82) 0.21 
Men (n;%) 0 1,397 (70%) 1,215 (70%) 382 (72%) 833 (68%) 0.09 182 (72%) 66 (76%) 116 (69%) 0.28 
IHD (n;%) 0 1,227 (61%) 1,062 (61%) 253 (48%) 809 (66%) <0.001 165 (65%) 48 (55%) 117 (70%) 0.02 
COPD (n;%) 0 214 (11%) 174 (10%) 45 (9%) 129 (11%) 0.19 40 (16%) 14 (16%) 26 (16%) 0.61 
 Diabetes (n;%) 0 494 (25%) 437 (25%) 127 (24%) 310 (25%) 0.54 57 (22%) 24 (28%) 33 (20%) 0.16 
 NYHA Class III/IV (n;%) 0 595 (31%) 491 (28%) 181 (34%) 310 (25%) <0.001 104 (41%) 37 (43%) 67 (40%) 0.71 
BMI (kg/m2) 53 29 (25-32) 29 (25-32) 28 (25-33) 29 (25-32) 0.82 28 (24-31) 29 (24-30) 28 (23-31) 0.85 
Heart Rate (bpm) 68 71 (60-84) 70 (60-83) 77 (66-90) 68 (59-79) <0.001 77 (65-88) 80 (69-92) 75 (63-85) 0.09 
Systolic BP (mmHg) 54 134 
(118-152) 
134 
(118-152) 
132 
(117-149) 
135 
(119-153) 
0.04 132 
(116-150) 
130 
(112-149) 
133 
(117-151) 
0.38 
Oedema (> trivial) 225 443 (22%) 357 (20%) 166 (32%) 191 (16%) <0.001 86 (34%) 32 (37%) 54 (32%) 0.74 
NT-proBNP (ng/L) 0 1,108 
(448-2,613) 
1,023 
(404-2,329) 
1,758 
(992-3,254) 
741 
(279-1,784) 
<0.001 2,428 
(941-5,532) 
3,187 
(1,548-5,700) 
1,996 
(774-5,208) 
0.01 
eGFR(4-variable) 
(ml/min/1.73m2) 
59 62 (48-76) 64 (51-77) 61 (48-74) 64 (52-78) 0.001 52 (35-67) 54 (35-68) 51 (37-65) 0.71 
Haemoglobin (d/dL) 63 13.5 
(12.3-14.6) 
13.6 
(12.4-14.7) 
13.8 
(12.6-15.0) 
13.5 
(12.4-14.6) 
0.003 12.9 
(11.6-14.4) 
13.0 
(11.8-14.5) 
12.9 
(11.5-14.3) 
0.42 
ACEi/ARB (n; %) 0 1,587 (79%) 1,399 (80%) 414 (79%) 985 (81%) 0.25 188 (74%) 65 (75%) 123 (74%) 0.86 
Beta blocker (n; %) 0 1,253 (63%) 1,117 (64%) 325 (62%) 792 (65%) 0.17 136 (54%) 53 (61%) 83 (50%) 0.09 
Diuretic (n; %) 0 1,516 (76%) 1,303 (75%) 426 (81%) 877 (72%) <0.001 213 (84%) 78 (90%) 135 (81%) 0.07 
Abbreviations: IHD: Ischaemic heart disease; COPD: Chronic obstructive pulmonary disease; NYHA Class: New York Heart Association classes; BMI: Body mass index; 
Systolic BP: Systolic blood pressure; eGFR: Estimated glomerular filtration rate; ACEi/ARB: Angiotensin-Converting enzyme inhibitors/angiotensin receptor blockers, SR: 
Sinus rhythm. 
* Comparison between groups of patients with SR and not SR. 
Table 2: Survival models using baseline log(NT-proBNP) only/adjusted for baseline age and 
sex; serial measurements of log(NT-proBNP); and most recent value of log(NT-proBNP) for 
all-cause mortality at 3 years 
 Log(NT-proBNP)  
HR (95%CI) z-statistic p-value c-statistic (SE) 
Baseline Cox model 3.05 (2.42-3.85) 9.42 <0.0001 0.67 (0.02) 
Model adjusted for age and sex 2.57 (2.02-3.28) 7.62 <0.0001 0.69 (0.02) 
     
Time-dependent Cox model 4.49 (3.54-5.70) 12.40 <0.0001 0.71 (0.02) 
Model adjusted for age and sex 3.92 (3.04-5.06) 10.58 <0.0001 0.73 (0.02) 
     
Most recent Cox model* 4.51 (3.57-5.71) 12.54 <0.0001 0.72 (0.02) 
Model adjusted for age and sex* 4.11 (3.20-5.29) 11.04 <0.0001 0.72 (0.02) 
* Models were generated using the same cohort but starting from the time of the most recent 
measurement of NT-proBNP 
